12:03 PM EDT, 05/14/2024 (MT Newswires) -- Novo Nordisk's ( NVO ) obesity drug Wegovy, or semaglutide, reduced major adverse cardiovascular events and sustained weight loss for up to four years in adults with pre-existing cardiovascular disease, overweight or obesity, but without diabetes, according to a Sunday report on new analysis of the results of the Select cardiovascular outcomes trial.

Wegovy showed a 20% reduction in major adverse cardiovascular events in over 17,600 adult patients from 41 countries, clinically meaningful weight loss in both sexes and across all races and body sizes, and improvements in anthropometric measurements, according to the report.

According to the new analysis, patients under the once-weekly, 2.4-milligram dose of Wegovy "lost significantly more weight than those receiving placebo."

CNBC said a second analysis of the trial's results showed that Wegovy also reduced the risk of heart disease regardless of a patient's weight. The report said both analyses were recently presented at the European Congress on Obesity in Venice, Italy.

Price: 132.17, Change: -0.24, Percent Change: -0.18